Breaking News

Heat Biologics Unveils Enhanced Allogeneic Cell Therapy Manufacturing Capabilities

Rolls out new 3-D allogeneic cell manufacturing capabilities through Scorpion subsidiary.

Author Image

By: Charlie Sternberg

Associate Editor

Heat Biologics Inc., a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, has unveiled enhanced allogeneic cell therapy manufacturing capabilities through its Scorpion Biological Services subsidiary.   Jeff Wolf, CEO of Heat, commented, “We are excited to rollout our new 3-D allogeneic cell manufacturing capabilities to replace our current 2-D HS-110 manufacturing. This new process is designed to in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters